For nearly 75 years, Dana-Farber Cancer Institute has demonstrated an equal commitment to research and care that is unique among cancer centers.
- Dana-Farber is a principal teaching affiliate of Harvard Medical School and a founding member of Dana-Farber/Harvard Cancer Center, one of 51 NCI-designated Comprehensive Cancer Centers.
- It provides the latest treatments in cancer for adults through Dana-Farber/Brigham and Women's Cancer Center and for children through Dana-Farber/Boston Children's Cancer and Blood Disorders Center.
- Dana-Farber is the top academic recipient of grant funding from the National Cancer Institute and its research efforts are far reaching.
- It has the most highly cited research of all U.S. cancer centers.
- In the last 10 years, nearly one of every four FDA-approved cancer drugs in the U.S. was developed in part with Dana-Farber Cancer Institute.
- Dana-Farber translates the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.
- Dana-Farber is the only hospital nationwide with a top 10 U.S. News & World Report "Best Hospitals" ranking in both adult and pediatric cancer care. In 2021, Newsweek ranked Dana-Farber third among the "World's Best Specialized Hospitals."
- Dana-Farber has made life-changing cancer advances, such as the discovery of the PD-L1 pathway and the EGFR mutation, which have helped to advance the development of immunotherapy and targeted therapies.
Dana-Farber's achievements result from our relentless fight against cancer. Since the founding of our organization in 1947 by Dr. Sidney Farber, the father of modern chemotherapy, Dana-Farber is building momentum which will continue to change the landscape of cancer.
